8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report: November 5, 2015

(Date of earliest event reported)

LOXO ONCOLOGY, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-36562	46-2996673
(Commission File Number)	(IRS Employer Identification No.)

One Landmark Square, Suite 1122 Stamford, CT	06901
(Address of Principal Executive Offices)	(Zip Code)

(203) 653-3880

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On November 5, 2015, Loxo and Dr. Jennifer Low announced Dr. Low would resign from the role of full-time Chief Medical Officer (“CMO”) and executive vice president, R&D. Over the next several months, Dr. Low plans to remain at Loxo Oncology as acting chief medical officer, as an employee through the end of 2015 and in an advisory role thereafter.

Loxo issued a press release announcing Dr. Low’s transitioning role on November 5, 2015, a copy of which is attached to this Form 8-K as Exhibit 99.1.

Item 9.01              Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description of Exhibit
99.1	Press Release dated November 5, 2015

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Loxo Oncology, Inc.
Date: November 5, 2015	By:	/s/ Joshua H. Bilenker
	Name:	Joshua H. Bilenker, M.D.
	Title:	Chief Executive Officer

3

EXHIBIT INDEX

Exhibit No.	Description of Exhibit
99.1	Press Release dated November 5, 2015

4

EX-99.1

Exhibit 99.1

Loxo Oncology Announces Transition of Chief Medical Officer

STAMFORD, Conn., November 5, 2015 — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Jennifer Low, M.D., Ph.D., chief medical officer and executive vice president, R&D, has decided to transition from her current role with Loxo Oncology. Over the next several months, Dr. Low will remain at Loxo Oncology as acting chief medical officer, as an employee through the end of 2015 and in an advisory role thereafter.

“I would like to thank Jennifer, a longtime friend, for her contributions during a formative period at Loxo Oncology,” said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. “With LOXO-101 enrolling in Phase 2, and our pipeline well-positioned for the clinic, the time was right for Jennifer to consider her next activities, both personally and professionally. Her transition has no effect on our current clinical plans or timelines, and I am confident we will continue to execute well against the full potential of our pipeline.”

“I am grateful for my time at Loxo Oncology and the opportunity to be part of its innovative approach to drug development. I have enjoyed experiencing the dynamic, entrepreneurial culture at Loxo, and transitioning out of my role at Loxo was a difficult decision,” stated Dr. Low. “The LOXO-101 program is one of the most exciting programs I have been involved with in my career and I’m proud to have helped put it on its path to success.”

About Loxo Oncology

Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company’s website at www.loxooncology.com.

Forward Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding the timing and success of our clinical trials and the potential therapeutic benefits and economic value of our lead product candidate.

Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q, and other reports as filed from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

###

Contacts for Loxo Oncology, Inc.

Company:
Jacob S. Van Naarden
Vice President, Corporate Development and Strategy
jake@loxooncology.com

Investors:

Peter Rahmer
The Trout Group, LLC
646-378-2973
prahmer@troutgroup.com

Media:

Dan Budwick
Pure Communications, Inc.
973-271-6085
dan@purecommunicationsinc.com